Recombinant Human Insulin is produced using genetically engineered organisms such as E. coli or Saccharomyces cerevisiae through recombinant DNA technology. It is a life-saving product for millions of diabetic patients and is among the most widely used biopharmaceuticals globally. Due to its complex production process and stringent quality regulations, insulin manufacturing involves significant investments in infrastructure, skilled labor, and compliance systems. Consequently, analyzing its production cost becomes essential for manufacturers aiming to remain competitive and cost-efficient.